Hospira Vinorelbine Tartrate for Injection 50 mg/5 mL vial

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Disponible desde:

Hospira Australia Pty Ltd

Designación común internacional (DCI):

Vinorelbine tartrate

formulario farmacéutico:

Injection

Composición:

Excipient Ingredients: water for injections

Vía de administración:

Intravenous

Unidades en paquete:

1 x 5 mL vial

clase:

Medicine Listed (Export Only)

tipo de receta:

Not scheduled. Not considered by committee

indicaciones terapéuticas:

Vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (NSCLC), as a single agent or in combination. Vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. In addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Resumen del producto:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2008-05-05